Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off t
Children in England with peanut allergies could be among the first in Europe to get access to Aimmune's oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS Engla
One of the first pharma victims of the current partial shutdown of the US government has emerged after the FDA said it would delay a review of a peanut allergy drug from Aimmune Therapeutic
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh